Risk Profile Improvements

  • Material Weakness (improved) — Previously disclosed material weakness in finance and accounting resources was remediated during Q2 2025.
NASDAQ: SNTI Senti Biosciences Holdings, Inc. 10-K

SENTI-202 wins FDA orphan & RMAT status; SN301A halted on toxicity; cash falls to $16M

Filed March 27, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 20, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade SNTI commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov View full financials on EDGAR ↗

Generated by AI · Jun 4, 2026 2:42 AM